As a sponsor of the CHCI Health Summit, Immunomic Therapeutics is pleased to support the initiatives of the event which include attracting and retaining greater diversity in clinical trials, ensuring equitable health outcomes for the Latino community and considering how the latest technological innovations will support Latino’s health needs.  Dr. Teri Heiland, Sr. VP R&D will discuss innovation during the closing plenary session and what companies like Immunomic can do to accelerate the development and approval of novel therapies, such as Immunomic’s investigational vaccines, for illnesses that greatly affect Latinos including cancer, allergy and infectious diseases.